NCT01172756

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction

Conditions

• Hypertension, Pulmonary
• Ventricular Dysfunction, Left

Interventions

Type	Name	Description
DRUG	Riociguat (BAY63-2521)	0.5 mg single oral dose
DRUG	Riociguat (BAY63-2521)	1 mg single oral dose
DRUG	Riociguat (BAY63-2521)	2 mg single oral dose
DRUG	Placebo	single oral dose

Timeline

• Start date: 2010-07-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2010-07-30
• Last updated: 2014-11-04

Locations

7 sites across 3 countries: Austria, Czechia, Germany